From: Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update
 | M ± SD | Range | Age | Comm | DLS | Soc | Motor | ABC | NVIQ | VIQ | FSIQ | Anatomical severity |
---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | r | r p | |||||||||
Serum, mg/dL (n = 30) |  |  |  |  |  |  |  |  |  |  |  |  |
 Cholesterol | 108.90 ± 32.39 | (47–181) | −.19 | .45* | .51** | .44* | .26 | .53** | .45* | .23 | .35 | −.19 |
 7-DHC | 5.70 ± 4.93 | (0.044–19.00) | .23 | −.25 | −.24 | −.47** | −.51* | −.31 | −.50** | −.30 | −.48* | .23 |
 8-DHC | 5.48 ± 5.29 | (0.14–28.00) | .11 | −.14 | −.07 | −.29 | −.29 | −.16 | −.36 | −.23 | −.35 | .11 |
 Ratio | 0.11 ± 0.10 | (0.0014–0.39) | .25 | −.43* | −.44* | −.59** | −.62** | −.50** | −.65** | −.41* | −.62** | .38* |
CSF, μg/mL (n = 26) |  |  |  |  |  |  |  |  |  |  |  |  |
 Cholesterol | 1.83 ± 0.58 | (0.96–3.66) | .02 | −.07 | −.13 | .02 | .03 | −.06 | .14 | −.08 | .07 | −.19 |
 7-DHC | 0.034 ± 0.028 | (0–0.097) | .47* | −.56** | −.54** | −.52** | −.68** | −.58** | −.52** | −.32 | −.51* | .24 |
 8-DHC | 0.072 ± 0.043 | (0.006–0.17) | .39* | −.48* | −.43* | −.32 | −.47* | −.46* | −.40* | −.30 | −.38 | .18 |
 Ratio | 0.065 ± 0.046 | (0.0028–0.15) | .38 | −.53** | −.52** | −.51** | −.66** | −.57** | −.59** | −.34 | −.56** | .32 |